Capeserod

Capeserod (INN, previously known as SL65.0155) is a selective 5-HT₄ receptor partial agonist with K_i = 0.6 nM and IA = 40–50% (relative to serotonin). It potently enhances cognition, learning, and memory, and also possesses antidepressant effects. Capeserod was in phase II clinical trials around 2004–2006 for the treatment of memory deficits and dementia but no new information has surfaced since and it appears to have been abandoned.